Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net ...

Kiniksa is shifting to next-gen IL-1 antibodies for recurrent pericarditis. Click here to read more on how this impacts KNSA ...

Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 –– KPL-387 Phase 1 single ascending dose ...

Learn more about whether AbbVie Inc. or Regeneron Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent pericarditis (RP) and reduction ...

Cardiovascular diseases specialist Kiniksa Pharmaceuticals International has announced updates to its pipeline alongside ...

Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 - - KPL-387 Phase 1 single ascending dose data support potential monthly dosing - - Kiniksa contin ...

Tarrytown, New York-based Regeneron Pharmaceuticals ... Libtayo, Evkeeza, Inmazeb Arcalyst, and Zaltrap. Zooming in further, REGN has also significantly underperformed the Health Care Select ...

ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent pericarditis (RP) and reduction ...

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...